Code Biotherapeutics

Code Biotherapeutics

  • Founded: 2021
  • Location: Hatfield, PA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: DMD
  • Drug types: GEN, MUS, END, IMM
  • Lead product: Undisclosed
  • Product link:
  • Funding: $75M A Jun 2022; $10M seed Apr 2021
  • Investors: Amgen Ventures, Hatteras Venture Partners, UCB Ventures, New Enterprise Associates, 4BIO Capital, CureDuchenne Ventures, the JDRF T1D Fund, UPMC Enterprises, Takeda Ventures

job board

Short description:

DNA-based Gene Therapy Vector

Drug notes:

Undisclosed RD diabetes (1)

Long description:

Code Biotherapeutics is using non-viral approaches to develop targeted delivery of genetic medicines. To rescue defects in genetic diseases DNA gene therapies can be employed, but they come with concerns and challenges. Using their proprietary, multivalent, synthetic DNA delivery platform, 3DNA®, Code Bio is overcoming the major challenges of DNA delivery such as toxicity, off-target effects and bioavailability. 3DNA® is a multivalent structure which acts as a scaffold for the attachment of nucleic acid based therapeutics and targeting molecules facilitating tissue and cell specificity. Currently, Code Bio is advancing a pipeline using their technology for diseases without a cure, such as Duchenne’s Muscular Dystrophy and Type I diabetes.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy